Natalie Diaz Cabrera, MD
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,339 of the $7,292 with a category attached, or 73.2%. 21 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 32.1% of the total. 2025 is the largest year on record at $2,279, 4.6 times the $499 reported in 2019.
Across 131 payments — averaging $55.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- AstraZeneca$2K
- GSK$692
- Sanofi$583
- Regeneron Healthcare Solutions, Inc.$544
- Biocryst US Sales Co., LLC$317
- plus $1K from 15 others
What the payments were for
- Consulting fees$1,80425%
- Speaking & faculty fees$501%
- Food & beverage$5,33973%
- Education$991%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $2,340 |
| AstraZeneca | 27 | $1,696 |
| GSK | 21 | $692 |
| Sanofi | 9 | $583 |
| Regeneron Healthcare Solutions, Inc. | 17 | $544 |
| Biocryst US Sales Co., LLC | 8 | $317 |
| Pharming Healthcare, Inc. | 7 | $236 |
| Genentech USA, Inc. | 3 | $191 |
| CSL Behring | 3 | $167 |
| Optinose US, Inc. | 5 | $104 |
| Pfizer | 3 | $59 |
| Amgen | 2 | $58 |
| Lilly USA, LLC | 2 | $55 |
| BD | 1 | $50 |
| Kaleo, Inc. | 2 | $44 |
| Aimmune Therapeutics, Inc. | 2 | $41 |
| AbbVie | 2 | $31 |
| Galderma Laboratories, L.p. | 1 | $26 |
| Merck | 1 | $20 |
| Novartis | 1 | $19 |
| Phadia US Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,292 in reported general payments places this provider in the 70th percentile of 56 allergy providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 30 | $66,130 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $15,529 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,626 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $3,663 |
| Azelastine Hcl | 51 | $1,527 |
| Ipratropium Bromide | 38 | $1,343 |
| Ammonium Lactate | 41 | $1,262 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $1,005 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 40 | $903 |
| Wixela InhubFluticasone Propion/Salmeterol | 13 | $569 |
| Triamcinolone Acetonide | 19 | $515 |
| Fluticasone Propionate | 23 | $364 |
| Levocetirizine Dihydrochloride | 55 | $285 |
| Hydroxyzine Hcl | 11 | $182 |
| Methylprednisolone | 12 | $123 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $692 | $20,15534 claims |
| AstraZenecaSymbicort | $1,696 | $3,66313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 56 allergy providers in Florida.
Other allergy in Miami
- Grace PadronMiami$5K
- Ana LamasMiami$2K
- Carlos PiniellaMiami$784
- Elena UbalsMiami$430
- Miguel LanzCoral Gables$778K
- Brett StanalandNaples$575K
- David RoseEglin Afb$253K
- Pavana BeerelliRockledge$61K
- Hugh WindomSarasota$37K
- Patrick de MarcoOrange Park$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.